Janvi Patel, PHD Student at Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), shared a post on LinkedIn about a paper she co-authored with colleagues published in Oncogene:
“I’m absolutely thrilled to share that our lab’s research work has been published in Oncogene (Nature Portfolio).
This study highlights how Dimerisation domain mutations (DDMs) cause signaling switches in HER2-positive breast cancer, which can drive therapeutic resistance – an insight that opens important avenues for developing improved treatment strategies specifically for patients harbouring these DDMs.
This milestone means even more to me as the leads from this work form the foundation of my ongoing PhD research, where I am deeply committed to advancing these findings toward clinical relevance.
This study is a true testament to insightful brainstorming discussions, well-planned experiments, and brilliant teamwork. It has been a privilege to work alongside Pranay Dey, Ph.D., whose visionary leadership made this possible. I would also like to sincerely thank Shivali Mishra for her unwavering support throughout this entire journey. I am forever grateful to our mentor Abhijit De for his constant guidance, encouragement, and for giving me the opportunity to contribute to this impactful work.
Looking forward to uncovering more insights from this work and taking meaningful steps toward clinical translation.”
Title: Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failure
Authors: Pranay Dey, Aniketh Bishnu, Janvi Patel, Shivali Mishra, Nikhil Gadewal, Pritha Ray, Sudeep Gupta, Abhijit De
You can read the Full Article in Oncogene.
More posts on Breast Cancer on OncoDaily.